Navigation Links
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
Date:11/15/2010

CHICAGO, Nov. 15, 2010 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

"Physicians and patients have long believed that a failing heart cannot be repaired, but the CUPID trial with MYDICAR adds support to other recent studies suggesting that the deterioration of heart function can indeed be slowed down, resulting in reduced hospitalizations and other cardiovascular events," said Donna Mancini, M.D., medical director of cardiac transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons, who presented the study's one-year results during the American Heart Association Scientific Sessions 2010. "I am very encouraged that our approach of restoring a critical enzyme that is depleted in such advanced patients will enhance our understanding of the human heart."

The study of 39 patients met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR versus placebo.  Additionally, after 12 months of receiving a single infusion of MYDICAR, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003), of major cardiovascular events such as:

  • Death
  • Need for left ventricular assist device (LVAD) or cardiac transplant
  • Episodes of worsening of heart failure
  • Number of heart failure-related hospitalizations

The mean duration of hospitalization in the MYDICAR high dose group during the 12-month period was 0.4 days per pat
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 One of ... rise of personalized medicine, which is the practice of ... treatments to a patient,s individual biology. Personalized diagnostics—laboratory analyses ... major role in the lab,s future. This fall, ... feature the latest science in this exciting field and ...
(Date:8/1/2014)... Once a decision has been made ... will discuss how to define your tolerance for lowest ... Allen, Senior Director of Facilities Integration at Fluor Industrial ... Industrial Services, and special guest Carrier Li, Director in ... as they provide an examination of the Conceptual Design ...
(Date:8/1/2014)... 01, 2014 Testing the mechanical ... a better understanding embryonic development. How and ... structurally and functionally distinct tissues is important because ... Prof. Todd McDevitt, Melissa Kinney, and Rabbia Saeed ... with biochemical cues to control many aspects of ...
(Date:7/31/2014)... CHICAGO , July 31, 2014 Nearly ... 65 th Annual Meeting & Clinical Lab Expo ... The meeting featured never-before-seen breakthroughs in diagnostic research and ... treatment they need. As of Wednesday, July ... 2014 AACC Annual Meeting & Clinical Lab Expo, with ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Study Links Biomechanics and Gene Expression in Stem Cells 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3
... Aug. 4 CryoLife, Inc. (NYSE: CRY ), ... Bruce G. Anderson has been promoted to vice president ... has been promoted to vice,president of international sales and ... vice president of worldwide sales and marketing.,Additionally, the company ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... royalty payment of approximately $2.1 million from ... for the treatment of,moderate-to-severe Alzheimer,s disease. Under ... royalty payments on certain,sales of Memantine by ...
... ALTO, Calif., Aug. 4 Anacor Pharmaceuticals,announced today that ... of Biological Research., "We are pleased to welcome ... President of Research at Anacor Pharmaceuticals. "Kurt,is a noted ... in,inflammation and his expertise will enrich our team as ...
Cached Biology Technology:CryoLife Announces Management Promotions 2CryoLife Announces Management Promotions 3Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research 2
(Date:8/1/2014)... have a more effective way to control the condition, ... the National University of Singapore (NUS). , The team, ... of Pharmacology at the NUS Yong Loo Lin School ... recent PhD graduate from the Saw Swee Hock School ... common herbal-based anti-malarial drug, can be used to control ...
(Date:7/31/2014)... study of bigeye tuna movements in the northwestern Atlantic ... Pelagics Research Center at the University of Massachusetts Amherst, ... wide geographical range with pronounced north-south movements from Georges ... high-use area off Cape Hatteras southwest of Bermuda for ... approach to study one of the most important commercial ...
(Date:7/31/2014)... 100 twin pairs have identified a gene mutation that may ... hours of sleep per night. The genetic variant also ... deprivation. , Results show that a participant with p.Tyr362His ... nightly sleep duration of only five hours, which was more ... for about six hours and five minutes per night. ...
Breaking Biology News(10 mins):NUS study shows effectiveness of common anti-malarial drug in controlling asthma 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3Study of twins discovers gene mutation linked to short sleep duration 2
... paleontologists have found fossilized burrows of tetrapods any land ... dating from the Early Triassic epoch, about 245 million years ... an overflowing river poured into the animals, burrows and hardened ... is about 14 inches long, 6 inches wide and 3 ...
... in Eastern Montana will now be able to chemically ... degrading begins. Paleontologists from Montana State University, North ... Natural Sciences recently bought and renovated a mobile laboratory ... for the summer. The lab is the first ...
... cell research, people are influenced by a number of ... many people. That,s the surprising finding ... who have spent the past two years studying public ... most recent issue of the International Journal of Public ...
Cached Biology News:Scientists find 245 million-year-old burrows of land vertebrates in Antarctica 2Dinosaur diggers bring mobile lab, new techniques to Eastern Montana 2Dinosaur diggers bring mobile lab, new techniques to Eastern Montana 3Scientific information largely ignored when forming opinions about stem cell research 2
... Gel loading solution, ... for non-denaturing polyacrylamide and ... nucleic acids and offers ... tracking dyes (bromphenol blue ...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... PCR Optimization Kits with ammonium sulfate are ... PCR, such as Tfl, Tth, and Pfu ... performance of PCR systems in one experiment ... PCR primers into the PreMixes supplied with ...
... the needs of the biopharmaceutical ... supports fast cell growth rates ... maintaining high cell viability and ... the Baculovirus Expression Vector System ...
Biology Products: